Arrive AI Inc. Q1 FY2026 earnings call

• One-Year Public Milestone: Arrive AI celebrated its one-year anniversary of listing on the NASDAQ under ticker ARAI, marking the completion of a multi-year journey to public markets. The company frames its progress similarly to early-stage pharmaceutical companies, measuring success by operational milestones rather than near-term financial results, with a key internal metric of "milestones per quarter (MPQ)".
• Product Development: Finalized a new manufacturing partnership in India to stabilize and optimize AP3 production, improving supply chain reliability, reducing costs, and speeding up unit delivery. An enhanced AP3 platform release is on track for July 2026, with broader commercial availability targeted for October 2026 to enable expanded customer onboarding. Development of the next-generation APX platform continues, with early prototypes expected in the coming development cycle; APX is designed to support large-scale commercial deployment across healthcare, enterprise delivery, and smart infrastructure. Foundational development for Arrive OS, the company's unifying software layer for network management and integrations, was completed in Q1, with a phased rollout planned for Q3 2026. All software development has been brought fully in-house, replacing legacy third-party systems, improving iteration speed, reducing costs, and giving Arrive AI full control over its technology stack.
• Operational and Commercial Milestones: The company now holds 10 issued U.S. utility patents, with 14 additional patent applications in the pipeline; it also has 77 pending international patent applications across 23 countries, with over 10 already issued or allowed. A large-scale public demonstration of the platform is targeted for late 2026 in Texas, to validate real-world functionality for customers, partners, and municipal stakeholders. The Hancock Health pilot continues to perform well, creating opportunities to showcase the platform to other potential customers, with additional deployment opportunities identified within Hancock Health. Experienced T-Mobile leader Mike Fitz joined the company's board of directors, bringing deep expertise in large-scale network and infrastructure operations.
• Financial and Governance Updates: The company ended Q1 2026 with $5.7 million in cash and $2.8 million in short-term investments (total $8.5 million in liquid assets), following a $10 million draw from its credit facility in January 2026. Quarterly cash burn is approximately $3 million, driven primarily by R&D and salary expenses. The company entered into a standstill agreement with investor Streeterville Capital through the end of 2026, which reduces stock price volatility from previous routine conversion activity, supports more orderly price discovery, and preserves flexibility for an orderly reduction of the remaining Streeterville balance during periods of high market liquidity. The company plans to file an SEC shelf registration statement to secure future financing optionality, with no immediate plans to raise new capital.

Arrive AI is an early-stage pre-commercial company, with limited current revenue. Total Q1 2026 revenue was $14,925, 100% of which came from recurring subscription revenue for deployed Arrive Points. Over 90% of this total revenue was generated from the Hancock Health deployment, with one additional small de minimis revenue contribution from a second minor deployment. No other segmented financial performance is reported, as the company has not yet launched scaled commercial operations across product segments.

• Product launch timeline guidance is maintained: Enhanced AP3 platform release remains on track for July 2026, with broader commercial availability starting October 2026; full commercial launch of next-generation APX platforms is targeted for the end of 2027.
• Arrive OS phased rollout is maintained to begin in Q3 2026.
• The large-scale Texas demonstration project is still guided to occur in late 2026.
• Quarterly cash burn is expected to remain near the current $3 million level through the next two quarters, with a modest increase projected for Q4 2026 as unit production and delivery scales up.
• With current cash and liquid investments, the company has approximately 8 months of operating runway at current burn rates without additional financing, and the shelf registration provides optionality to access lower-cost capital when needed, supporting execution through 2027 and beyond.

• Arrive AI is an early-stage company in an emerging market, with limited current revenue and no guarantee of future commercial success or scalable recurring revenue generation.
• Drone deployment is currently restricted by U.S. regulatory requirements that force reliance on visual observers, increasing operational costs and making drone-focused unit economics unviable at present; regulatory changes are required to unlock drone deployment opportunities both domestically and internationally.
• Future commercial growth and expansion will require additional new capital over the next several years, and there is no guarantee that the company will be able to secure financing on acceptable terms.
• Deployment capacity has been limited by manufacturing constraints to date, which has constrained the pace of customer onboarding and revenue growth, even with the new supply chain partnership.
• Stock price volatility tied to prior Streeterville Capital conversion activity created material market uncertainty, though the standstill agreement is expected to mitigate this risk.

Q: How repeatable is the successful Hancock Health healthcare deployment, and what is the opportunity for healthcare vertical expansion? / A: Management notes that the Hancock Health deployment is a very valuable showcase that highlights the platform's ability to reduce labor burdens for healthcare workers, a persistent and growing issue driven by nationwide nursing shortages. Additional new deployment opportunities have already been identified within Hancock Health, and the showcase has driven strong inbound interest from other potential healthcare customers, making the vertical highly repeatable.

Q: How does Arrive AI prioritize U.S. domestic growth versus international expansion opportunities? / A: The company follows a "home first" strategy to prioritize efficient allocation of limited capital and human resources. Iterating close to home allows for faster learning that can be directly integrated into next-generation product development. While many international markets have looser regulations that could enable faster iteration, the added cost of supporting international deployments at this early stage makes domestic focus the highest priority for now.

Q: What is the company's current cash runway, and how should investors think about upcoming cash needs? / A: The company ended Q1 with $8.5 million in total cash and short-term investments, which provides approximately 8 months of runway at the current $3 million quarterly burn rate. The recently completed standstill agreement with Streeterville Capital removes the prior headwind of unexpected conversion volatility, and $19 million in remaining capacity is still available on the Streeterville facility if needed. The upcoming shelf registration will give the company optionality to raise lower-cost capital when the time is right, leaving the company well-positioned to execute its near-term plan.

Q: What will catalyze commercialization growth, and when will sales and marketing scale? / A: Management notes that the autonomous delivery market is reaching a boiling point of convergence across drone, robotic, and infrastructure segments, growing awareness of Arrive AI's unique value proposition. The Hancock deployment has already hosted dozens of potential customer groups, driving growing inbound interest. The major step-function catalyst for larger commercial deployments will be the launch of the next-generation APX platform, which is targeted for the end of 2027, after the ongoing digital demo and AP3 refinement phases.